Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2005-07-12
2005-07-12
Harris, Alana M. (Department: 1642)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S193100, C424S195110, C424S282100, C424S277100, C424S278100, C514S023000, C514S025000
Reexamination Certificate
active
06916476
ABSTRACT:
This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of ganglioside or oligosaccharide portion thereof conjugated to an immunogenic protein effective to stimulate or enhance antibody production in the subject, an effective amount of adjuvant and a pharmaceutically acceptable vehicle.
REFERENCES:
patent: 4356170 (1982-10-01), Jennings et al.
patent: 4557931 (1985-12-01), Irie et al.
patent: 4591552 (1986-05-01), Neurath
patent: 4652629 (1987-03-01), Patrick et al.
patent: 4879213 (1989-11-01), Fox et al.
patent: 5102663 (1992-04-01), Livingston et al.
patent: 5256409 (1993-10-01), Blincko
patent: 5344870 (1994-09-01), Ratcliffe et al.
patent: 5599914 (1997-02-01), Wiegand et al.
patent: 5616477 (1997-04-01), Price
Livingston, Proc. Natl. Acad. Sci, USA, 84: 2911-2915, 1987.
Fiume, L. et al. Critical Reviews in Therapeutic Drug Carrier Systems, 4(4): 265-284, 1988.
Burgess et al. J. Cell Biol. 111:2129-38, Nov. 1990.
Lazar et al Mol. Cell. Biol. 8(3):1247-52, Mar. 1988.
Sollgnller et al. Cancer Immunol. Immunother. 39:105-116, 1994.
Cohen et al. Science 262: 841-843, Nov. 1993.
J.A. Parson (EJ.) “Peptide Hormones”, See Chapter 1, pp 1-7, Jun. 1976.
Fung P.Y.S. et al., “Active Specific Immunotherapy of a Murine Mammary Adenocarcinoma Using a Synthetic Tumor-Associated Glycoconjugate”, Cancer Research, Jul. 15, 1990, vol. 50, pp. 4308-4314 (Exhibit 4).
Kensil R.C., et al., “Separation and Characterization of Saponins With Adjuvant Activity fromQuillaja SaponariaMolina Cortex”, The Journal of Immunology, Jan. 15, 1991, vol. 146, No. 2, pp. 431-437 (Exhibit 5).
Livingston P.O., et al., “Characterization of IgG and IgM Antibodies Induced in Melanoma Patients by Immunization with Purified GM2Ganglioside”, Cancer Research, Dec. 15, 1989, vol. 49, pp. 7045-7050 (Exhibit 6).
Livingston P.O., et al., “Studies on the Immunogenicity of Synthetic and Natural Thomsen-Friedhenreich (TF) Antigens in Mice: Augmentation of the Response by Quil A and SAF-m Adjuvants and Analysis of the Specificity of the Responses”, Vaccine Research, vol. 1, No. 2, 1992, pp. 99-109 (Exhibit 7).
MacLean G.D et al., “Immunization of Breast Cancer Patients Using a Synthetic Sialyl-Tn Glycoconjugate Plus Detox Adjuvant”, Cancer Immunol. Immunother., vol. 36, 1993, pp. 215-222 (Exhibit 8).
MacLean G.D., et al., “Active Immunization of Human Ovarian Cancer Patients Against a Common Carcinoma (Thomsen-Friedenreich) Determinant Using a Synthetic Carbohydrate Antigen”, Journal of Immunotherapy, vol. 11, 1992, pp. 292-305 (Exhibit 9).
Marciani D.J., et al., “Genetically-engineered Subunit Vaccine Against Feline Leukaemia Virus: Protective Immune Response in Cats”,Vaccine, vol. 9, Feb. 1991, pp. 89-96 (Exhibit 10).
Newman J.M., et al., “Saponin Adjuvant Induction of Ovalbumin-Specific CD8+Cytotoxic T Lymphocyte Responses”, The Journal of Immunology, vol. 148, No. 8, Apr. 15, 1992, pp. 2357-2362 (Exhibit 11).
Ritter G., et al., “Ganglioside Antigens Expressed by Human Cancer Cells”, Seminars in Cancer Biology, vol. 2, 1991, pp. 401-409 (Exhibit 12).
Ritter G., et al., “Antibody Response to Immunization with Purified GD3 Ganglioside and GD3 Derivatives (Lactones, Amide and Gangliosidol) in the Mouse”, Immunobiol., 1990, vol. 182 pp. 32-43 (Exhibit 13).
Wu J-Y. et al., “Saponin Adjuvant Enhancement of Antigen-Specific Immune Responses to an Experimental HIV-1 Vaccine”, The Journal of Immunology, vol. 148, 1992, pp. 1519-1525 (Exhibit 14).
Helling, F., et al. “Increased immunogenicity of GM2 conjugated with KLH and used with adjuvants in patients with melanoma.” Mar. 1993Proceedings Of The 84th Annual Meeting Of The American Association For Cancer Research34: 491.
Helling, F., et al. “Construction of immunogenic GD-3 conjugate vaccines.” Aug. 1993Annals Of The New York Academy Of Sciences690: 396-397.
Helling, F., et al. “GD-3 vaccines for melanoma superior immunogenicity of key hole limpet hemocyanin conjugage.” 1994Cancer Research54: 197-203.
Bystryn, J-C. “Tumor vaccines.” 1990 Cancer And Metastasis Reviews, 9: 81-91.
Ritter, G., et al. “Antibody response to immunization with ganglioside GD3 and GD3 congeners (lactones, amide and gangliosidol) in patients malignant melanoma.” 1991,Int. J. Cancer48: 379-385.
Helling Friedhelm
Livingston Philip Ordway
Cooper & Dunham LLP
Harris Alana M.
Holleran Anne L.
Sloan-Kettering Institute for Cancer Institute
White, Esq. John P.
LandOfFree
Ganglioslide-KLH conjugate vaccine plus QS-21 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ganglioslide-KLH conjugate vaccine plus QS-21, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ganglioslide-KLH conjugate vaccine plus QS-21 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3391872